Applications for global Cryoimmunostaining™ technology trial now open

Bangkok, July 2018 – After successfully completing a series of clinical trials across Southeast Asia, atypical cell detection specialist X-ZELL is now making the company’s patented Cryoimmunostaining™ technology available to research organisations around the globe.

“After a very promising series of trials in Southeast Asia we are now recruiting research institutes from around the world to gain first-hand feedback on the usability of our world-unique Cryoimmunostaining™ equipment,” explained X-ZELL CEO, Dr Sebastian Bhakdi.

“We are looking for researchers open to pushing the boundaries of immunostaining and willing to help us get the most of next-generation rare cell detection technology.”

According to Dr Bhadki, X-ZELL is committed to “real world problem-solving, which is why we continue to make our core technology available to independent researchers from different scientific fields.”

While X-ZELL itself is successfully using Cryoimmunostaining™ technology for early prostate cancer detection – with a range of additional liquid biopsies currently in the works – he pointed out that the equipment trial is not limited to cancer detection. “There is only one restriction,” he said. “Just like us, successful applicants must ensure they focus on patient outcomes.”

Dr Bhakdi said X-ZELL’s platform technology might also prove advantageous for single cell detection, staining of cryosections, as well as melanoma and lymph node research.

Successful applicants will receive full access to X-ZELL’s patented Cryoimmunostaining™ platform technology – including X-ZELL’s suite of reagents, buffers and CapGap™ equipment – as well as ongoing support from X-ZELL’s global engineering team for the duration of the project.

To apply, contact X-ZELL Inc on and include a brief outline of the proposed project, including a (tentative) timeline. Note participation is strictly limited*.

* X-ZELL reserves the right to reject any application without assigning any reason thereto.


Media Contact:
Sebastian Grote
Head of Marketing & Communications

Next-generation cytology

© 2024 X-ZELL Biotech Pte. Ltd.

Find Us